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of patients with mania associated to Bipolar Disorder assessed by change in the Young 
Mania Rating Scale (YMRS) score and Clinical Global Impression (CGI) score from 
inclusion to day 21. Quality of life and safety/tolerability were measured with the 
Euro Quality of Life 5D (EQ5D), Work Productivity and Activity Impairment, Barnes 
Akathisia Rating Scale, Simpson-Angus Scale, physical examinations, adverse events, 
change of weight and other adverse events of special interest. The efﬁ cacy analysis 
was based on the modiﬁ ed intention-to-treat population, that included all patients 
who received study medication and who had a YMRS assessment at inclusion and at 
least one YMRS valid assessment after inclusion resulting in a total of 88 patients. 
RESULTS: YMRS total score reduction in 21 days was 20.55 points (95% CI, 
22.82–18.27); P < 0.0001. CGI total score decreased in 2.41 units, (95% CI, 2.69–
2.13); P < 0.0001. The EQ5D index increased 0.21 points (95% CI, 0.16–0.27) P < 
0.0001. The EQ5D Visual Analog Scale increased 23.49% (95% CI, 16.36%–
30.61%); P < 0.0001. CONCLUSIONS: Overall results shown in this study demon-
strate an improvement in the control of patients in maniac phase of bipolar disorder 
with an increase in Quality of Life.
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OBJECTIVES: For therapeutic augmentation of impaired cholinergic transmission in 
Alzheimer Disease (AD), Acetylcholine-Esterase-inhibitors (ACHE-I; galantamine, 
donepezil, rivastigmine) are approved therapies in mild to-moderate AD. The NMDA 
receptor partial antagonist (memantine) is licensed for therapy of moderate–severe 
AD. In order to inform clinical decision-making about efﬁ cacy, safety and broader 
non-cognitive outcomes, we identiﬁ ed evidence from comparative and non-compara-
tive studies. METHODS: A comprehensive search was conducted on Medline, 
Embase, conference abstracts and the Cochrane Library aimed to identify all ran-
domised, placebo controlled trials (RCTs) reporting efﬁ cacy and/or safety outcomes 
and randomised, controlled comparative trials. In a second step, trials with drug 
dosing outside the approved European Summary of Product Characteristics were 
excluded. Eligibility of trials was assessed by two blinded reviewers; quality of trials 
were assessed by CONSORT. Meta-analyses were performed, reporting ﬁ xed and 
random effects using comparative analytical techniques. RESULTS: Fifty—eight 
studies fulﬁ lled the inclusion criteria. In 45 trials, ACHE-I were tested against placebo, 
in 9 trials against another ACHE-I. For memantine, 9 placebo-controlled trials were 
identiﬁ ed. In most trials, patients were treated between 12–30 weeks; 9 RCTs reported 
longer-term outcomes, up to 24 months. After critical appraisal, 33 studies were 
included in further analyses. Meta-analysis of effects on cognition (ADAS-cog, MMSE, 
SIB) showed superiority of at least one ACHE-I versus placebo at the 3 months, 6 
months and longer-time timepoint. Results for memantine indicated non-signiﬁ cant 
improvement at any assessed timepoint. Behavioural outcomes were less well reported 
but showed superiority versus placebo for galantamine and memantine measured by 
the Neuropsychiatric Inventory Scale. CONCLUSIONS: There is abundant evidence 
for the efﬁ cacy, safety and tolerability of ACHE-Is in the treatment of patients with 
mild to moderate AD. Data for improved behavioural functioning is limited though 
available for galantamine and memantine.
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BACKGROUND: In our age and gender speciﬁ c analyses for calendar year 2003, we 
observed an administrative prevalence rate of ADHD in Nordbaden (a region in the 
South-West of Germany with a population of >2.7 million) of 0.53%, with a peak 
among 9-year old boys at 8.43%. From 2003 to 2008, methylphenidate prescriptions 
(deﬁ ned daily doses, DDDs) in Germany increased 2.65-fold, raising concern about 
potentially inappropriate use. OBJECTIVES: To establish a longitudinal ADHD 
patient database and to assess changes of ADHD administrative prevalence rates by 
age and gender during the period from 2003 to 2008, in order to lay the foundation 
for further analyses of treatment and prescribing patterns. METHODS: The complete 
claims database of the organization of physicians registered with statutory health 
insurance [SHI] (Kassenaerztliche Vereinigung, KV) in Nordbaden/Germany was 
available for analysis, covering the total regional population enrolled in SHI (>2.2 
million). Age and gender speciﬁ c 1-year prevalence rates of ADHD were determined 
for years 2003 through 2008. RESULTS: During the 6-year period under study, the 
overall one-year ADHD prevalence rate increased from 0.53% to 0.90%. ADHD 
(hyperkinetic disorder: ICD-10, F90.0, F90.1) prevalence rates were highest in the age 
group 6–12 years (peak [2008] among nine-year-old children, 9,55%; boys, 12,31%), 
increasing continuously during the observation period (a) age group 6–12: from 
4.75% (boys, 6.91%; girls, 2.46%) to 7.62% (boys, 10.44%; girls, 4.66%); (b) age 
group 13–17: from 1.73% (boys, 2.66%; girls, 0.75%) to 3.78% (boys, 5.69%; girls, 
1.74%); adults (age >18 years): from 0.04% (males, 0.05%; females, 0.03%) to 
0.14% (males, 0.18%; females, 0.10%). CONCLUSIONS: German methylphenidate 
prescription growth outpaced the increase in ADHD diagnoses from 2003 to 2008. 
Further research seems warranted and has been initiated with regard to the underlying 
dynamics of physician group involvement, coexisting conditions, utilization patterns 
(treatment duration, intensity, switches), and regarding economic implications.
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OBJECTIVES: From tales of Christian tradition to essays of 17th century physicians, 
Friday has been identiﬁ ed as a day of ill luck. Amongst all Fridays of the year however 
the one coinciding with the 13th day of the month is known to be associated with 
extreme misfortune. Therefore, the fate of persons born on Friday the 13th (F13) 
warrants investigation. We investigated the effect of being born on Friday the 13th 
on the prevalence of a) cancer; b) diabetes; c) mental health disorders; and d) sexual 
disorders. METHODS: Persons born on Friday the 13th were identiﬁ ed from a drug 
utilization database. To control for seasonal variation and time-trends, persons born 
on Friday the 6th and Friday the 20th were selected as controls. Differences in pre-
scription prevalences were analyzed using multivariate logistic regression. RESULTS: 
A total of 4202 cases and 8987 controls were identiﬁ ed. The number of cases was less 
than expected based on the number of controls (expected number 4396, P < 0.01), 
suggesting a survival disadvantage for F13 cases. Age (32.8 ± 22.6 vs. 32.7 ± 23.0) 
and gender (53.1% vs. 53.3% female) were similar. Multivariable logistic regression 
showed no increase in prescription prevalences for F13 cases (P > 0.1 for all drug 
classes). Exploratory analyses showed that F13 cases being prescribed antipsychotics 
were younger than controls (P = 0.03) and diabetic cases were more often male (P = 
0.04). CONCLUSIONS: Although attenuating effects of survivor selection bias cannot 
be ruled out, the current study found no scientiﬁ c basis for paraskavedekatriaphobia 
in relation to drug utilization. Signiﬁ cant differences in age and gender for speciﬁ c 
subgroups may be attributed to the multiple comparison issue. Results will be pre-
sented on interaction effects of Friday the 13th coinciding with full-moon (n = 154) 
and good Friday (n = 113).
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OBJECTIVES: To examine the standardized mortality ratio (SMR) in inpatients with 
schizophrenia and related psychosis. METHODS: To compare the mortality risk in 
Japanese with psychosis with that of the general population, we utilized two large 
studies, called “the JESS2000” and “the JESS2000 Follow-up Study.” In the JESS2000 
study, 2,309 psychotic patients who had been hospitalized in Japanese national mental 
hospitals as of September 1, 2000 were included. In the JESS2000 Follow-up Study, 
the JESS2000 patients were followed up and those who had died as of September 1, 
2005 were identiﬁ ed retrospectively. The expected number of deaths was calculated 
by multiplying the number of patients in each gender- and age-speciﬁ c subgroup by 
the mortality rate derived from the Japanese abridged life table and adding all of the 
ﬁ gures in each of these subgroups. The SMR was calculated by the observed number 
of deaths, identiﬁ ed in the JESS2000 Follow-up Study, divided by the expected 
number. RESULTS: Of 2309 original samples, 56.3% were male. On September 1, 
2000, the mean age (SD) was 52.0 (14.6) years. The mean duration of hospitalization 
was 10.3 (12.0) years. The mean age at onset of psychosis was 23.7 (7.9) years. The 
deaths of 204 patients were conﬁ rmed as of September 1, 2005. Of these 204 deceased 
patients, 13 committed suicide, 6 died from accidents and 148 died of natural causes. 
No information regarding cause of death for the remaining 16 patients could be 
obtained. The expected numbers of deaths in this cohort was 100.67. Therefore the 
SMR for all causes in this cohort was estimated at 2.03 or more. CONCLUSIONS: 
Our ﬁ ndings were similar to the results of the systematic review by Saha et al., which 
reported the SMR for schizophrenia as 2.58. 
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OBJECTIVES: To evaluate the ﬁ nancial consequences of sertindole reimbursement for 
the Polish National Health Fund (NHF) budget. METHODS: Budget impact analysis 
was performed in a 3-year time horizon from two perspectives of NHF and a patient. 
Costs of oral antipsychotic drugs and EKG test of patients treated with sertindole were 
included. Two future scenarios were estimated: 1) with reimbursement of sertindole, 
and 2) without sertindole reimbursement. Target population was estimated using 
